Impact of myokines on chronic liver diseases: exploring the effects of metabolic dysfunction-associated steatotic liver disease (MASLD) on skeletal muscle. A narrative review

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition characterized by altered liver function due to fatty accumulation, which can lead to liver inflammation and, in advanced stages, liver carcinoma. MASLD is closely linked to several metabolic alterations, such as obesity...

Full description

Bibliographic Details
Published in:	European Journal of Translational Myology
Main Authors:	Francisco Aguirre, Mayalen Valero-Breton, Daniel Cabrera, Luis Peñailillo, María Carolina Otero, Claudia Fredes, Claudio Cabello-Verrugio
Format:	Article
Language:	English
Published:	PAGEPress Publications 2025-07-01
Subjects:	Metabolic dysfunction-associated steatotic liver disease sarcopenia myokines
Online Access:	https://www.pagepressjournals.org/bam/article/view/13365

Similar Items

Myokines and Their Potential Protective Role Against Oxidative Stress in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: José Luis Bucarey, et al.
Published: (2024-11-01)

Exerkines and myokines in aging sarcopenia
by: Huan Wang, et al.
Published: (2025-07-01)

Emerging Insights into the Pathogenic Mechanisms of Myokines and Hepatokines in Muscle-liver Crosstalk: Implications for Non-alcoholic Fatty Liver Disease and Sarcopenia
by: Ziwei Gu, et al.
Published: (2024-09-01)

Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Thaninee Prasoppokakorn
Published: (2025-01-01)

Advances in the research on myokine-driven regulation of bone metabolism
by: MingHong Shao, et al.
Published: (2024-01-01)

Sarcopenia and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review
by: Ludovico Abenavoli, et al.
Published: (2024-09-01)

Association between metabolic dysfunction‐associated steatotic liver disease and myosteatosis measured by computed tomography
by: Myung Jin Kim, et al.
Published: (2024-10-01)

The role and mechanisms of myokines in sarcopenia: new intervention strategies for the challenges of aging
by: Xiangran Cui, et al.
Published: (2025-10-01)

ASSOCIATION BETWEEN ANXIETY AND DEPRESSION IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
by: Eloyse Cristina BOTACIN, et al.
Published: (2024-07-01)

Circulating Myokines as Novel Biomarkers for Cardiovascular Diseases
by: Jin-xiu Lyu, et al.
Published: (2024-02-01)

Serum Irisin, Myostatin, and Myonectin Correlate with Metabolic Health Markers, Liver Disease Progression, and Blood Pressure in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease and Hypertension
by: Anna F. Sheptulina, et al.
Published: (2024-10-01)

Exercise-induced myokines in health and metabolic diseases
by: Byunghun So, et al.
Published: (2014-12-01)

Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Soyeon Shin, et al.
Published: (2023-12-01)

Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Amani Elshaer, et al.
Published: (2024-07-01)

A new Korean nomenclature for steatotic liver disease
by: Nonalcoholic Fatty Liver Disease (NAFLD) Nomenclature Revision Consensus Task Force on behalf of the Korean Association for the Study of the Liver (KASL)
Published: (2024-09-01)

Skeletal Muscle, Myokines and Health
by: Halil Duzova
Published: (2012-09-01)

Mitochondria Homeostasis and Oxidant/Antioxidant Balance in Skeletal Muscle—Do Myokines Play a Role?
by: Brian Pak Shing Pang, et al.
Published: (2021-01-01)

Role of Myokines in Regulating Skeletal Muscle Mass and Function
by: Jong Han Lee, et al.
Published: (2019-01-01)

Pathogenic Mechanisms of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Associated Hepatocellular Carcinoma
by: Toru Nakamura, et al.
Published: (2025-03-01)

Quercetin: A Promising Candidate for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
by: Julia Markowska, et al.
Published: (2024-11-01)

Predictive factors for metabolic syndrome in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
by: Mohammad Alnees, et al.
Published: (2025-08-01)

Interplay of Oxidative Stress, Gut Microbiota, and Nicotine in Metabolic-Associated Steatotic Liver Disease (MASLD)
by: Irene Mignini, et al.
Published: (2024-12-01)

Evaluation of Liver Fibrosis through Noninvasive Tests in Steatotic Liver Disease
by: Yuri Cho
Published: (2024-11-01)

Pathogenic aspects of fructose consumption in metabolic dysfunction-associated steatotic liver disease (MASLD): A narrative review
by: Katharina Burger, et al.
Published: (2025-06-01)

The Dual Role of Myokines in Fatigue Associated with Inflammatory Joint Diseases
by: Chmielewski G, et al.
Published: (2025-09-01)

FGF21 as a hepatokine, adipokine, and myokine in metabolism and diseases
by: Nobuyuki eItoh
Published: (2014-07-01)

Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
by: Bing Yang, et al.
Published: (2022-09-01)

Role of myokines in regulation of a power exchange
by: V. I. Scherbakov, et al.
Published: (2012-06-01)

Effect of a Ketogenic Diet on Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Progression: A Randomized Controlled Trial
by: Sakkarin Chirapongsathorn, et al.
Published: (2025-01-01)

Diagnosis and management of metabolic dysfunction- associated steatotic liver disease in South Asians- A clinical review
by: Prajith Raj Ramesh, et al.
Published: (2024-12-01)

Treatment of HCV infection in patients with steatotic liver disease
by: Robert Flisiak, et al.
Published: (2024-07-01)

Corrigendum: Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis
by: Bing Yang, et al.
Published: (2023-09-01)

Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on “Epidemiology of metabolic dysfunction-associated steatotic liver disease”
by: Lin Guan, et al.
Published: (2025-04-01)

Stratified cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): impact of varying metabolic risk factor burden
by: Maha Elsabaawy, et al.
Published: (2025-09-01)

Myokines: Do they really exist?
by: Yasuko Manabe, et al.
Published: (2012-08-01)

Phosphorylation: new star of pathogenesis and treatment in steatotic liver disease
by: Tiansu Lv, et al.
Published: (2024-02-01)

Research advance of myokines on bone metabolism regulation
by: ZHOU Bing-na, LI Mei
Published: (2021-12-01)

METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: UPDATE
by: Maria Gabriela Fernandes DEZAN, et al.
Published: (2025-09-01)

Beneficial effects of voluntary over forced exercise on skeletal muscle structure and myokines’ expression
by: M. A. Eldomiaty, et al.
Published: (2020-06-01)

The association between cardiometabolic index (CMI) and metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis
by: Alireza Azarboo, et al.
Published: (2025-08-01)